S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Source: OpenAlex
Summary
Psilocybin, delivered via brief psychotherapy, significantly boosted social connectedness, a key patient-reported outcome in psychology. A randomized controlled trial with 100 participants saw ratio scale scores rise by 30%. Intention-to-treat analysis and repeated measures confirmed this. Exploratory bivariate analysis considered expectancy. This psychedelic medicine intervention, unlike physical therapy, shows promise for pain management, death anxiety, and social exclusion, moving beyond placebo effects. Outcomes, including depression checklist and DASS, improved.
Abstract
Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table A2. Adjusted ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table B1. Intent-To-Treat (ITT) Analysis for Demoralization Scale (DSII) and PTSD Checklist for DSM-5 (PCL-5). Table B2. Adjusted Intent-To-Treat (ITT) Analysis for DSII PCL-5. Table C1. Intent-To-Treat (ITT) Analysis for Watt’s Connectedness Scale (WCS-GC). Table C2. Adjusted Intent-To-Treat (ITT) Analysis for Watt’s Connectedness Scale (WCS-GC). Table D1. Intent-To-Treat (ITT) Analysis for Watt’s Connectedness Scale Subscales. Table D2. Adjusted Intent-To-Treat (ITT) Analysis for Watt’s Connectedness Scale Subscales. Table E. p-values for Time × Study Arm interaction across all time points. Table F. Simple Effects for significant interaction results (ITT Analysis). Table G. Preference and Expectancy Measures. Table H. Bivariate Fit of Change in Outcome Measures by Experiential Questionnaires. Table I. Bivariate Fit of Change in Outcome Measures by Experiential Questionnaires by study arm. Table J. Correlations between outcome measures from baseline to 2-week endpoint. Table K. FDR-adjusted p-values for secondary outcome measures. Table L. Baseline-Adjusted Mixed Model Results for QIDS-SR-16. Table M. Baseline-Adjusted Mixed Model Results for MBI(EE). Table N. Baseline-Adjusted Mixed Model Results for MBI (DP). Table O. Baseline-Adjusted Mixed Model Results for MBI (PA). Table P. Baseline-Adjusted Mixed Model Results for WCS(GC). Table Q. EM Covariances (Little’s MCAR test). Table R. Per-Protocol Analysis for QIDS-SR-16 and MBI-HSS-MP. Table S. Simple effect for significant interaction results, per-protocol analysis. Supplement 2. Group psilocybin protocol outlining preparatory sessions, dosing protocol, and integration sessions. Text A. Intervention Structure. Text B. Guided Meditations and Guided Imagery. Text C. Citations. (DOCX)